Webcast

The Insider: Meet the CEOs – 8 December

December 8, 2021

The Insider: Meet the CEOs – 8 December

The Insider: Meet the CEOs Webcast Replay

We were joined by the CEOs of exciting ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.

  • Far East Gold Limited – Justin Werner, Non-Executive Director
  • (ASX: RD1) Registry Direct Limited – Steuart Roe, Founder & CEO
  • (ASX: AVE) Avecho Biotechnology Limited – Dr Paul Gavin, CEO

Recorded on 8th December 2021 at 12pm (AEDT).

Join the next The Insider: Meet the CEOs webcast

Speak to the Reach Markets team

FEATURED SPEAKERS

Justin Werner

Non-Executive Director - Far East Gold Limited

Far East Gold is an Australian exploration company with gold and copper mining operations across more than 45,000 hectares in Indonesia and Australia. The company has identified six advanced projects with multiple walk-up drill targets, including a project with a JORC 2012 resource estimate of 996,500 ounces of gold. Far East Gold is led by an experienced board and management team who have raised more than $1 billion in funding and have a successful Indonesian track record of mine development. The company is scheduled to list on the ASX in January 2022, following which it is targeting the finalisation of acquisitions and expansion of operations, including JORC estimates for remaining sites.

Steuart Roe

Founder & CEO - Registry Direct Limited (ASX: RD1)

Registry Direct is a fintech company offering the only fully featured software-as-a-service (SaaS) registry management platform in Australia. The company’s technology positions them as a disruptor in an industry that has become increasingly regulated with greater operating, reporting and compliance obligations. Registry Direct’s platform is used by some of the world’s largest companies, including Tesla, Facebook and Starbucks, as well as fund managers and private companies. With its proven technology and revenue model, the company is well-placed to capitalise on opportunities in a significant addressable market.

Dr Paul Gavin

CEO - Avecho Biotechnology Limited (ASX: AVE)

Avecho develops and commercialises innovative human and animal health products using its proprietary drug delivery system Tocopheryl Phosphate Mixture (TPM). TPM is the world’s first and only drug delivery platform produced using a patented process that combines two different forms of tocopheryl phosphate, an enhanced form of vitamin E. The platform increases the bioavailability of drugs it delivers by 4-40 times, thereby increasing the effectiveness of the drug and reducing dosage. Avecho operates in, among others, the global cannabidiol market, which is expected to grow to US$55 billion by 2028.

Speak to the Reach Markets team




What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.